A Sophisticated Ratiometric Nuclear Medicine Imaging Strategy for Biological Microenvironment Abnormal Factor Detection.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40059506.
- Also identified by DOI 10.1002/adhm.202404914.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Biological microenvironment detection is crucial for deciphering the mechanisms underlying malignant progression and predicting the treatment efficacy of diseases. Nevertheless, only very limited progress has been made toward non-invasive and quantitative detection of microenvironment abnormal factors, let alone with clinically compatible imaging modalities. Herein, a smart nuclear medicine probe is proposed, innovatively designed for quantitative visualization of glutathione (GSH) in vivo. This probe contains a disulfide bond that links two molecular segments labeled with <sup>125</sup>I and <sup>177</sup>Lu, respectively. Upon systemic delivery, the probe preferentially accumulates in the liver, where GSH cleaves it into two fragments with completely different metabolic fates: one retained at the response site and the other rapidly excreted. This unique feature provides an opportunity to use the <sup>177</sup>Lu/<sup>125</sup>I signal ratio to non-invasively characterize the GSH concentration in vivo, enabling highly sensitive quantification of GSH that is strongly associated with many hepatic diseases. Moreover, the strategy also provides a reliable method for the quantitative visualization of GSH levels in tumors. It is thus believed the current study provides a groundbreaking method for non-invasively and quantitatively revealing disease-related microenvironment factors, not limited to GSH, in vivo.
Medical subject headings
- Glutathione
- Tumor Microenvironment
- Nuclear Medicine